XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio Dec 02, 2024 7:30am EST
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities Nov 07, 2024 7:30am EST
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience Oct 22, 2024 8:00am EDT
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) Sep 23, 2024 6:30am EDT
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities Aug 13, 2024 7:30am EDT
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher Jun 12, 2024 7:30am EDT
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ May 14, 2024 7:30am EDT
